Patents by Inventor María OCHOA DE OLZA

María OCHOA DE OLZA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD-ECGF AS BIOMARKER OF CANCER
    Publication number: 20240069029
    Abstract: The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.
    Type: Application
    Filed: October 27, 2023
    Publication date: February 29, 2024
    Inventors: Oriol CASANOVAS CASANOVAS, Gabriela JIMÉNEZ VALERIO, María OCHOA DE OLZA, Valentí NAVARRO PÉREZ, Nicklas BASSANI, Helena VERDAGUER
  • PD-ECGF as biomarker of cancer
    Patent number: 11802874
    Abstract: The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: October 31, 2023
    Assignees: FUNDACIO INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL), INSTITUT CATALÀ D'ONCOLOGIA (ICO)
    Inventors: Oriol Casanovas Casanovas, Gabriela Jiménez Valerio, María Ochoa De Olza, Valentí Navarro Pérez, Nicklas Bassani, Helena Verdaguer
  • PD-ECGF AS BIOMARKER OF CANCER
    Publication number: 20180052164
    Abstract: The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.
    Type: Application
    Filed: March 10, 2016
    Publication date: February 22, 2018
    Applicants: FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL), INSTITUT CATALÀ D'ONCOLOGIA (ICO)
    Inventors: Oriol CASANOVAS CASANOVAS, Gabriela JIMÉNEZ VALERIO, María OCHOA DE OLZA, Valentí NAVARRO PÉREZ, Nicklas BASSANI, Helena VERDAGUER